June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Evaluation of the effect of intravitreal bevacizumab injection on the visual outcome following vitreous haemorrhage with PDR
Author Affiliations & Notes
  • IBRAHIM TASKINTUNA
    Vitreoretinal Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • Maram E A Abdalla Elsayed
    Jeddah Eye Hospital, Jeddah, Saudi Arabia
  • Rajiv Khandekar
    King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • Patrik Schatz
    Vitreoretinal Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
    Dept of Ophthalmology, University of Lund, Lund, Sweden
  • Igor Kozak
    Vitreoretinal Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
    Moorfield Eye Hospital Centre, Abu Dhabi, United Arab Emirates
  • Footnotes
    Commercial Relationships   IBRAHIM TASKINTUNA, None; Maram E A Abdalla Elsayed, None; Rajiv Khandekar, None; Patrik Schatz, None; Igor Kozak, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5042. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      IBRAHIM TASKINTUNA, Maram E A Abdalla Elsayed, Rajiv Khandekar, Patrik Schatz, Igor Kozak; Evaluation of the effect of intravitreal bevacizumab injection on the visual outcome following vitreous haemorrhage with PDR. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5042.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Complications of Proliferative diabetic retinopathy (PDR) is leading cause of severe visual loss in the working age group worldwide. Vitreous haemorrhage has traditionally been managed by observation or pars plana vitrectomy (PPV) since the Diabetic Retinopathy Vitrectomy Studies in the late 80's. In the current study, we investigated the effect of intravitreal avastin (IVAV) injection on the visual outcome following diabetic vitreous haemorrhage.

Methods : Retrospective study from a single tertiary referral center (KKESH, Riyadh, KSA).One hundred forty five eyes of 145 patients with diabetic vitreous haemorrhage were divided into 4 groups as follows: Observation group (group 1, n=40), PPV group (group 2, n=41), preoperative single IVAV injection followed by PPV (group 3, n=22), and IVAV injections group (group 4, n=42). The primary outcome was corrected distance visual acuity (CDVA) at last follow-up ( months) after the presentation of vitreous haemorrhage. The median duration of follow up was 10.8 months. Analysis of variance was used to assess if there were significant differences across groups with respect to CDVA.

Results : The baseline CDVA was similar across all groups (p=0.5). There was a trend for better CDVA in the IVAV injection group at last follow-up (p=0.05), with the proportion of eyes having CDVA 20/20 to 20/60 as follows: Group 1 (22.5%), group 2 (34.1%), group 3 (45.5%), group 4 (59.5%). The proportion of patients with poor metabolic control (blood sugar level higher than 7 mmol/dl) was significantly higher in group 4 (p=0.005). Age, gender, prevalance of hypertension and nephropathy did not differ significantly between groups.

Conclusions : There was a trend towards better visual outcome with intravitreal avastin injection compared to observation or PPV for management of diabetic vitreous haemorrhage.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×